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Abstract
Background: An understanding of host cell factors that affect viral replication contributes to elucidation of the
mechanism for determination of viral tropism. Cyclophilin A (CypA), a peptidyl-prolyl cis-trans isomerase (PPIase), is
a host factor essential for efficient replication of human immunodeficiency virus type 1 (HIV-1) in human cells.
However, the role of cyclophilins in simian immunodeficiency virus (SIV) replication has not been determined. In
the present study, we examined the effect of cyclosporine A (CsA), a PPIase inhibitor, on SIV replication.
Results: SIV replication in human CEM-SS T cells was not inhibited but rather enhanced by treatment with CsA,
which inhibited HIV-1 replication. CsA treatment of target human cells enhanced an early step of SIV replication.
CypA overexpression enhanced the early phase of HIV-1 but not SIV replication, while CypA knock-down resulted
in suppression of HIV-1 but not SIV replication in CEM-SS cells, partially explaining different sensitivities of HIV-1
and SIV replication to CsA treatment. In contrast, CsA treatment inhibited SIV replication in macaque T cells; CsA
treatment of either virus producer or target cells resulted in suppression of SIV replication. SIV infection was
enhanced by CypA overexpression in macaque target cells.
Conclusions: CsA treatment enhanced SIV replication in human T cells but abrogated SIV replication in macaque
T cells, implying a host cell species-specific effect of CsA on SIV replication. Further analyses indicated a positive
effect of CypA on SIV infection into macaque but not into human T cells. These results suggest possible
contribution of CypA to the determination of SIV tropism.
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Background
Viral replication is modulated by host cell factors, with
the species specificity of these factors affecting viral
tropism. Some of these host factors can restrict viral
replication. The anti-viral systems mediated by such
host restriction factors, termed intrinsic immunity, play
an important role in determining species-specific bar-
riers against viral infection. For instance, Fv-1 in mice is
known to restrict replication of a murine leukemia virus
[1-3]; and tripartite interaction motif 5a (TRIM5a)
recently has been found to be responsible for restricting
human immunodeficiency virus type 1 (HIV-1), but not
simian immunodeficiency virus (SIV) infection in old
world monkey (OWM) cells [4-9]. Restriction of retro-
viral replication by these host cell factors takes place
after viral entry, but before the integration step; and the
viral determinants for this type of restriction have been
mapped to the capsid (CA) protein [1,3,10-12]. Under-
standing how host cell factors affect viral replication,
positively or negatively, would contribute to elucidating
the molecular mechanism that determines viral tropism.
Cyclophilin A (CypA), a peptidyl-prolyl isomerase, is a
host cell factor essential for efficient HIV-1 replication in
human cells [13-19]. CypA promotes an early step in
HIV-1 replication, after viral entry but before reverse
transcription [20]. Late in replication, during virus
assembly, CypA is incorporated into progeny HIV-1 vir-
ions through CypA interaction with viral CA [13,14,18].
Disruption of CypA incorporation by Gag mutations or
by treatment of infected cells with cyclosporine A (CsA),
a PPIase inhibitor, results in a reduction in the infectivity
of the progeny viruses produced [13,14,16,21-24].
Furthermore, interaction of viral CA with CypA in target
cells after viral entry has been shown to promote HIV-1
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for an early step of HIV-1 replication in human cells
[15,19,25,26].
In contrast, the effect of CypA on SIV replication has
not been well-documented, although a possible interac-
tion between CypA and SIV CA has been indicated
[17,27,28]. A recent study has shown a suppressive effect
of CypA on replication of vif-deleted SIV in human
Jurkat cells, which was counteracted by SIV Vif inhibiting
CypA incorporation during virus assembly [27]. This Vif
function can be distinguished from its anti-human APO-
BEC3G (apolipoprotein B mRNA-editing enzyme-cataly-
tic subunit 3G) function.
In the present study, we have investigated the effect of
CsA on wild-type SIV replication in human or macaque
T cells. SIV replication in human T cells was not inhib-
ited but rather enhanced by treatment with CsA, which
inhibits HIV-1 replication. In contrast, CsA treatment
abrogated SIV replication in macaque T cells, indicating
a species-specific effect of CsA on SIV replication. CypA
knock-down or overexpression suggested that CypA
affects SIV replication differently in human and macaque
T cells and suggested possible contribution of CypA to
the determination of SIV tropism.
Results
Effect of CsA treatment on SIV replication in human T cells
We investigated the effect of CsA treatment on wild-type
SIV replication in human CEM-SS T cells. Replication of
wild-type SIVagm, SIVmac, and HIV-1 in the presence of
CsA was compared with that in the absence of CsA (Fig-
ure 1A). Consistent with previous reports, CsA treatment
inhibited the packaging of CypA into HIV-1 particles
(Figure 1B) and impaired HIV-1 replication in CEM-SS
cells (Figure 1A). CypA was incorporated into SIVagm
and SIVmac progeny virions, although not efficiently,
and CsA treatment further abrogated this low level of
CypA incorporation (Figure 1B) without the reduction of
endogenous CypA (data not shown). Interestingly, how-
ever, CsA treatment did not inhibit but rather enhanced
SIV replication in CEM-SS cells (Figure 1A). This CsA-
mediated enhancement of SIV replication was also
observed in human A3.01 T cells (Figure 1C).
Effect of CsA treatment of target human T cells on SIV
infection
Recent studies have indicated that CypA in target cells is
crucial for an early HIV-1 replication step in human cells
[15,19,25,26,29]. We therefore studied the effect of CsA
treatment of target cells on SIV infection. Viruses were
produced from CsA-untreated or CsA-treated CEM-SS
cells and used to infect CsA-untreated or CsA-treated
target human LuSIV cells. Cell lysates were prepared
from the target LuSIV cells 24 h post-infection, and
luciferase activity was measured to assess the efficiency
of SIV infection (Figure 2A). Similar to the results in
Jurkat cells [27], CsA treatment of either the producer
cells or the target cells resulted in suppression of HIV-1
infection confirming the importance of CypA both in
producer and target human cells for efficient HIV-1
replication [16,30]. In contrast, SIVagm infection was not
inhibited but rather enhanced by CsA treatment of target
cells although it was decreased by CsA treatment of pro-
ducer cells. Similarly, SIVmac infection was not inhibited
by CsA treatment of target cells but decreased by CsA
treatment of producer cells.
Infection efficiency was also determined by measuring
the amounts of viral cDNA synthesized in target CEM-SS
cells after viral infection by quantitative PCR (Figure 2B).
As a negative control, cells were also infected with heat-
inactivated viruses. Consistent with the above results
(Figure 2A), the amounts of viral cDNA synthesized after
HIV-1 infection were reduced by CsA treatment of target
cells (Figure 2B). In contrast, CsA-mediated effect on
viral cDNA synthesis after SIV infection into CEM-SS
cells (Figure 2B) was consistent with the results shown in
Figure 2A. CsA treatment did not inhibit SIV infection in
another human T cells, A3.01, either (data not shown).
Thus, CsA treatment of human producer cells reduced
infectivity of progeny SIVs, whereas CsA treatment of
human target cells did not inhibit but rather enhanced
SIV infection.
Effect of CypA knock-down on SIV replication in human
T cells
To examine the effect of CypA on SIV replication in
CEM-SS cells, we established CypA knocked-down
(CypA-KD) CEM-SS cell lines. CypA expression in
CEM-SS CypA-KD cells was stably suppressed by
CypA-specific shRNA (Figure 3). We confirmed that
both cell proliferation and cell surface levels of CD4 and
CXCR4 that are required for HIV-1 entry showed no
difference between parental CEM-SS and CypA-KD
CEM-SS cells (data not shown). As previously reported
[16], CypA knock-down reduced viral cDNA synthesis
after HIV-1 infection (Figure 4A) and inhibited HIV-1
replication (Figure 4B). In CypA-KD CEM-SS cells, CsA
treatment showed little effect on viral cDNA synthesis
after HIV-1 infection, indicating that CypA inhibition
was largely involved in CsA-mediated reduction of HIV-
1 infection. In contrast, CypA knock-down did not
reduce viral cDNA synthesis after SIV infection (Figure
4A) or SIV replication (Figure 4B). These results indi-
cate that target cell CypA is essential for HIV-1 infec-
tion but not required for SIV infection into human T
cells. CsA treatment, however, enhanced SIV replication
even in CypA-KD cells (Figure 4A and 4B, SIVagm),
suggesting the possibility that CsA neutralizes the
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Page 2 of 16Figure 1 SIV and HIV-1 replication in human cells. (A) SIV and HIV-1 replication kinetics in CEM-SS cells. CEM-SS cells were infected with
SIVagm (top panel), SIVmac (middle panel), and HIV-1 (bottom) in the absence (CsA[-], closed circles) or presence of 2.5 μM CsA (CsA[+], open
circles). Virus production was monitored by measuring RT activity in the culture supernatants. (B) CypA incorporation into virions. Virus-
containing supernatants were harvested from CsA-untreated and CsA-treated CEM-SS cells infected with SIVagm, SIVmac and HIV-1. A mock-
infected sample was included as a control. CypA-specific band densities were quantified by densitometric scanning and are plotted in the lower
panel. For each virus, the density of the band from CsA-untreated cells was defined as 100% and the ratio (%) of the density of the band from
CsA-treated cells to that from CsA-untreated cells was calculated. The image of one representative blot is shown. (C) SIVagm replication kinetics
in A3.01 cells.
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Page 3 of 16Figure 2 Effect of CsA treatment of target human T cells on SIV infection. (A) Effect of CsA treatment of producer human CEM-SS or target
human LuSIV cells on viral infectivity. SIVagm, SIVmac, and HIV-1 from producer CEM-SS cells in the absence (Producer CEM-SS cell CsA [-]) or
presence of CsA (Producer CEM-SS cell CsA [+]) were used to infect CsA-untreated (Target LuSIV cell CsA [-]) or CsA-treated target LuSIV cells
(Target LuSIV cell CsA [+]). Luciferase activity in target LuSIV cells was measured 24 hr after infection. Relative infectivity is shown as the ratio (%)
of the luciferase activity to that of viruses produced from CsA-untreated CEM-SS in CsA-untreated LuSIV cells. Mean values and standard
deviations in four independent experiments are shown. (B) Effect of CsA treatment of producer or target human cells on viral replication.
SIVagm, SIVmac, and HIV-1 from producer CEM-SS cells in the absence (Producer cell CsA [-]) or presence of CsA (Producer cell CsA [+]) were
used to infect CsA-untreated (Target cell CsA [-]) or CsA-treated target CEM-SS cells (Target cell CsA [+]). Heat-inactivated virus was used as an
infection control. Relative viral cDNA levels are shown as the ratio (%) of the viral cDNA levels to that of virus produced from CsA-untreated
CEM-SS in CsA-untreated CEM-SS cells. Mean values and standard deviations in six independent experiments are shown.
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Page 4 of 16residual CypA population which remains in the CypA-
KD cells as shown by Western blotting in Figure 3, or
the possible involvement of another host factor in this
CsA-mediated enhancement of SIV replication. Similar
to the results obtained by replication in CypA-KD
CEM-SS cells, the effect of CypA knock-down on SIV
infection or SIV replication was also observed in A3.01
cells (data not shown).
We also established a cyclophilin B (CypB), another
PPIase, knocked-down (CypB-KD) CEM-SS cell line
(Figure 5A). Overall SIV replication was enhanced in
CypB-KD cells (Figure 5B, SIVagm). As predicted,
HIV-1 replication was not affected by the CypB knock-
down (Figure 5B, HIV-1). These results suggest that the
CsA-induced enhancement of SIV replication in human
T cells observed in Figure 1A is mediated largely if not
exclusively by an inhibition of CypB.
Effect of CsA treatment on SIV replication in macaque T
cells
We next examined the effect of CsA treatment on SIV
replication in macaque cells using three macaque T-cell
lines: cynomolgus macaque-derived HSC-F, rhesus
macaque-derived HSR-5.4, and pig-tailed macaque-
Figure 3 Immunoblot analysis of CypA expression. Lysates of CEM-SS (normal), CypA-KD cells were subjected to the analysis using anti-CypA
antibodies. Anti-a-tubulin antibody was used as loading control. The ratio (%) of CypA band density in CypA-KD to that in normal CEM-SS is
shown at the bottom panels. The image of one representative blot is shown.
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Page 5 of 16Figure 4 Effect of CypA knock-down on SIV and HIV-1 replication in human CEM-SS cells. (A) The amounts of viral cDNA synthesized after
SIVagm (left panel), SIVmac239 (middle panel) or HIV-1 (right panel) infection. Viruses produced from CEM-SS cells were used to infect CsA-
untreated or CsA-treated target CEM-SS, CypA-KD cells. Heat-inactivated virus was used as an infection control. The synthesized viral cDNA levels
were measured by real-time PCR. Mean values and standard deviations in six independent experiments are shown. Relative viral cDNA levels are
shown as the ratio (%) of the viral cDNA levels to that of viruses produced from CsA-untreated CEM-SS in CsA-untreated CEM-SS cells. (B)
Replication of SIVagm (left panels) or HIV-1 (right panels) in CypA-KD CEM-SS cells. Viral production in normal CsA-untreated CEM-SS (closed
circles), CsA-untreated (closed squares) or CsA-treated CypA-KD (open squares) was monitored by measuring RT activity in the culture
supernatants.
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Page 6 of 16derived Mn-3942 (Figure 6). Both SIVmac239 and
SIVagm replicated well in all three cell lines, with the
most efficient replication in HSC-F cells. However, in
contrast to the results above for SIV replication in
human T cells, CsA treatment inhibited SIVagm replica-
tion in all three macaque T cell lines. This inhibitory
effect of CsA on SIV replication was also observed in
rhesus macaque PBMCs (Figure 6). The CsA effect on
HSC-F cell proliferation was marginal and not consid-
ered as responsible for this inhibition of SIV replication.
Indeed, treatment of these macaque cells with lower
concentration (0.5 μM) of CsA had no effect on cell
proliferation but resulted in inhibition of SIV replication
(data not shown). CypA was incorporated into SIV vir-
ions in the absence of CsA, but its incorporation was
inhibited by CsA treatment of HSC-F cells (Figure 7A)
without the reduction of endogenous CypA (data not
shown). HIV-1 replication was undetectable in these
macaque T-cell lines even in the presence of CsA (data
not shown), although the possibility of enhancement of
HIV-1 infection by CsA treatment in OWM cell lines
has been indicated previously [28,31,32]. Thus, SIV
Figure 5 Effect of CypB knock-down on HIV-1 and SIV replication in human CEM-SS T cells. (A) Immunoblot analysis of CypB expression.
Lysates of CEM-SS (normal), CypA-KD, and CypB-KD cells were subjected to the immunoblot analysis using anti-a-tubulin, anti-CypA and anti-
CypB antibodies (Abcam Inc., Cambridge, MA) (left panel). CypA- and CypB-specific band densities were quantified by densitometric scanning
and are plotted in the right panels. The image of one representative blot is shown. (B) Replication of SIVagm (left panels) or HIV-1 (right panels)
in CypB-KD CEM-SS cells. Viral production in normal CEM-SS (closed circles) or CypB-KD cells (closed triangles) was monitored by measuring RT
activity in the culture supernatants.
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Page 7 of 16replication in macaque T cells is inhibited by CsA treat-
ment, indicating the exact opposite effect of CsA on SIV
replication in macaque T cells than in human T cells.
We then examined the effect of CsA treatment of pro-
ducer or target macaque HSC-F cells on SIV infection
(Figure 7B). Measurement of synthesized viral cDNA
Figure 6 SIV replication in macaque cells. Cynomolgus macaque HSC-F, rhesus macaque HSR-5.4, pig-tailed macaque Mn-3942, and rhesus
macaque PBMCs (rhPBMC) were infected with SIVagm (left panels) and SIVmac (right panels) and cultured in the absence (CsA[-], closed circles)
or presence of 2.5 μM CsA (CsA[+], open circles). Virus production was monitored by measuring RT activity in the culture supernatants.
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Page 8 of 16Figure 7 Effect of CsA treatment of macaque T cells on SIV infection. (A) Efficiency of CypA incorporation into virions from producer
macaque HSC-F cells. Culture supernatants were harvested from CsA-untreated mock, and CsA-untreated and CsA-treated HSC-F cells infected
with SIVagm. The CypA incorporation efficiency (right panel) is shown as described in the legend for Figure 1B. The image of one representative
blot is shown. (B) Effect of CsA treatment of producer or target macaque HSC-F cells on SIV replication. SIVagm and SIVmac produced from HSC-
F cells in the absence (Producer cell CsA [-]) or presence of CsA (Producer cell CsA [+]) was used to infect CsA-untreated (Target cell CsA [-]) or
CsA-treated target HSC-F cells (Target cell CsA [+]). Heat-inactivated virus was used as an infection control. Relative viral cDNA levels are shown
as the ratio (%) of the viral cDNA levels to that of virus produced from CsA-untreated HSC-F in CsA-untreated HSC-F cells. The synthesized viral
cDNA levels were measured by real-time PCR. Mean values and standard deviations in four independent experiments are shown.
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Page 9 of 16levels in target cells infected with SIV from CsA-
untreated or CsA-treated producer HSC-F cells showed
that SIV from CsA-treated producer HSC-F cells had
lower amount than that from CsA-untreated producer
HSC-F cells. In contrast to the results in human CEM-
SS cells (Figure 2B), CsA treatment of target HSC-F
cells did not increase viral cDNA synthesis after SIV
infection, but rather resulted in a reduction in synthesis.
Thus, CsA treatment of macaque T cells has an inhibi-
tory effect on a post-entry step of SIV replication.
Effect of exogenous CypA on SIV infection in human and
macaque T cells
Our attempts to knock down CypA in macaque HSC-F
cells were unsuccessful. We therefore examined and
compared the effect of CypA overexpression in target
CEM-SS and HSC-F cells on SIV infection. We first
examined the effect of exogenously expressed CypA in
human target cells on SIV replication. CEM-SS or
CypA-KD cells were transfected (nucleofected) with
plasmids expressing HA-control or CypA-HA, respec-
tively. Transfected cells were enriched by magnetic
beads sorting as described in Methods. More than 97%
of sorted cells were shown to express the marker pro-
tein (H-2K
k) without a reduction in cell-surface CD4
levels (data not shown).
We found that exogenous CypA increased HIV-1
cDNA synthesis in CsA-treated CEM-SS cells (Figure
8A), confirming the positive effect of target cell CypA
on the early phase of HIV-1 replication. However, SIV
infection was not affected by exogenous CypA expres-
sion even in CsA-treated CEM-SS cells (Figure 8A). In
contrast, CypA overexpression in HSC-F target cells did
not reduce but rather enhanced viral cDNA synthesis
after SIV infection (Figure 8B). These results suggest
that target cell CypA essential for HIV-1 infection is not
largely involved in SIV infection in human T cells but
has a positive effect on SIV replication in macaque T
cells.
Effect of CsA treatment of target cells on human cell- or
macaque cell-derived SIV infection
We then investigated how the infectivity of SIV from
producer macaque cells is affected by CsA treatment of
target human cells and how the infectivity of SIV from
producer human cells is affected by CsA treatment of
target macaque cells. We first measured viral cDNA
levels in target human CEM-SS cells after infection with
SIV from producer macaque HSC-F cells (Figure 9A).
Similar to the results obtained by infection of CEM-SS
cells with CEM-SS-derived SIV (Figure 2), CsA treat-
ment of target CEM-SS cells enhanced infection by
HSC-F-derived SIV. These data indicate that even maca-
que cell-derived SIV infection is enhanced by CsA
treatment of target human cells. Finally, we examined
the effect of CsA on the infectivity of CEM-SS-derived
SIV in macaque HSC-F cells (Figure 9B). The results
were similar to those for infection of HSC-F cells by
HSC-F-derived SIV (Figure 7B), i.e. CsA treatment of
either producer or target cells diminished infectivity of
CEM-SS-derived SIV in HSC-F cells, although previous
reports showed that the role of virion-associated CypA
i sm i n o rc o m p a r e dt ot h a to ft a r g e tc e l lC y p A
[15,19,25,26,29].
Discussion
The present study showed that CsA treatment, which
inhibits HIV-1 replication, does not inhibit but rather
enhances SIV (SIVmac239 and SIVagm) replication in
human T cells. In SIV infection of both CEM-SS and
A3.01 cells, CsA treatment resulted in production of
viruses with lower infectivity but enhanced an early step
of replication. The present study indicates that CsA
treatment exerts different effects on the early phase of
HIV-1 and SIV replication in human T cells. Indeed,
previous study also showed the positive effect of CsA on
HIV-1 and SIV vectors infection in primary mouse cells,
suggesting different effects of CsA on the early phase of
HIV-1 between human and mouse cells [33]. Addition-
ally, we found that expression level of CCR5 on cell sur-
face was lower than that of CXCR4 in CEM-SS cells
(data not shown). This may be due to different kinetics
between CCR5-tropic SIV and CXCR4-tropic HIV-1 in
Figure 1A.
Knock down of CypA, an essential host factor for
HIV-1 replication, did not reduce SIV replication in
human T cells. CypA knock-down in target human
cells, which inhibited HIV-1 infection, did not reduce
viral cDNA synthesis after SIV infection, indicating that
target human cell CypA is essential for HIV-1 but not
for SIV infection. These results imply different effects of
CypA on HIV-1 and SIV replication in human T cells.
Our results revealed that CypA can be incorporated
into SIV virions although not very efficiently. This is
consistent with previous results [27,34]. A previous
study implied inhibition of viral replication by over-
incorporation of CypA in vif-deleted SIV [27], whereas
the present study suggests that low levels of CypA pro-
teins incorporated into wild-type SIV do not inhibit but
may rather contribute to SIV replication in human T
cells. Two amino acids in HIV-1 Gag, Gly221 and
Pro222, were found to be important for the binding of
CypA [21]. Although two amino acids are in fact con-
served in our SIVagm isolate, the same region is not
conserved in SIVmac239, which also was found to
encapsidate CypA (Figure 1B). Therefore, it seems that
CypA is incorporated into SIV virions through a
mechanism that is distinct from HIV-1.
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Page 10 of 16Target human cell CypA was shown to be essential for
HIV-1 but not for SIV infection. This may partially
explain different sensitivities of HIV-1 and SIV replica-
tion to CsA treatment, although other unknown host fac-
t o r sc o u l da l s ob ei n v o l v e di nt h eC s A - m e d i a t e d
enhancement of SIV replication in human T cells.
Indeed, CsA treatment enhanced SIV replication even in
CypA-KD cells (Figure 4B). We also attempted to exam-
ine the effect of cyclophilin B (CypB), another CsA-sensi-
tive PPIase, on SIV replication by knock-down of CypB
(Figure 5). CypB knock-down showed no significant
effect on HIV-1 replication but enhanced SIV replication
in human T cells, suggesting a possible involvement of
CypB in SIV replication. Overall SIV replication was
enhanced in CypB-KD cells (Figure 5B, SIVagm) and
CsA treatment resulted in only slight enhancement of
SIV replication (data not shown). As predicted, HIV-1
replication was not affected by the CypB knock-down
(Figure 5B, HIV-1) but was inhibited by CsA treatment
(data not shown). Thus, enhanced replication of SIV in
CsA-treated human cells as shown in Figure 1A might be
best explained by the neutralization of CypB’s inhibitory
effect. Previous reports showed that CypB can bind to
both HIV-1 and SIV CA [14,35], but CypB incorporation
into HIV-1/SIV virions was undetectable in the present
study (data not shown). Regarding the cellular localiza-
tion of CypB, association of CypB with the endoplasmic
reticulum (ER) via an ER signal sequence has been
reported [36]. In other reports [37-39], CypB has been
shown to be associated with heparan sulfate proteogly-
cans (HSPG) on the cell surface. Overall, it remains
unclear how CypB affects SIV infection directly or indir-
ectly, because most CypB is believed to express in the
endoplasmic reticulum but not in cytoplasm [40].
In contrast, CsA treatment inhibited SIV (SIVmac239
and SIVagm) replication in macaque T cells; CsA treat-
ment of either virus producer or target cells resulted in
suppression of SIV replication. This CsA effect on SIV
replication in macaque T cells is similar to that on HIV-1
replication in human T cells. Although our attempts to
Figure 8 Effect of exogenous CypA expression on SIV and HIV-1 replication. (A) The amounts of viral cDNA synthesized after SIVagm (left
panel) or HIV-1 (right panel) infection in human CEM-SS cells. Viruses produced from normal CEM-SS cells were used to infect CsA-untreated or
CsA-treated target normal CEM-SS cells. Heat-inactivated virus was used as an infection control. Relative viral cDNA levels are shown as the ratio
(%) of the viral cDNA levels to that of viruses produced from CsA-untreated CEM-SS in CsA-untreated CEM-SS cells. Mean values and standard
deviations in three independent experiments are shown. (B) The amounts of viral cDNA after SIVagm infection in macaque HSC-F cells. SIVagm
produced from normal HSC-F cells was used to infect CsA-untreated or CsA-treated target normal HSC-F cells. Heat-inactivated virus was used as
an infection control. Relative viral cDNA levels are shown as the ratio (%) of the viral cDNA levels to that of viruses produced from CsA-untreated
HSC-F in CsA-untreated HSC-F cells. Mean values and standard deviations in three independent experiments are shown.
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Page 11 of 16Figure 9 Infection of human and macaque cells with macaque- and human-derived SIV. (A) SIVagm and SIVmac produced from HSC-F
cells in the absence or presence of CsA were used to infect CsA-untreated or CsA-treated target CEM-SS cells. Relative viral cDNA levels are
shown as the ratio (%) of the viral cDNA levels to that of viruses produced from CsA-untreated HSC-F in CsA-untreated CEM-SS cells. Mean
values and standard deviations in three independent experiments are shown. (B) SIVagm and SIVmac produced from CEM-SS cells in the
absence or presence of CsA were used to infect CsA-untreated or CsA-treated target HSC-F cells. Relative viral cDNA levels are shown as the
ratio (%) of the viral cDNA levels to that of viruses produced from CsA-untreated CEM-SS in CsA-untreated HSC-F cells. The relative viral cDNA
levels synthesized were measured by real-time PCR. Mean values and standard deviations in three independent experiments are shown.
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Page 12 of 16knock down CypA in macaque HSC-F cells were unsuc-
cessful, we have obtained CypA knocked-down rhesus
macaque kidney cell line: LLC-MK2 cells (Additional
File 1). Analysis using these cells revealed that CypA is
inhibitory for SIV replication in macaque cells and indi-
cated that CypA dysfunction is likely to be largely
involved in CsA-mediated reduction of SIV replication in
macaque cells (Additional File 1). Taken together, the
current study reveals that CsA treatment inhibited SIV
replication in macaque T cells but enhanced SIV replica-
tion in human T cells, indicating a host species-specific
effect of CsA on SIV replication. These data suggest that
the effect of CsA on SIV infection seems to be general
properties of SIV in human and macaque T cells, and
cyclophilins may contribute to host-range control of cer-
tain lentiviruses.
Sequence analyses of CypA cDNA from human CEM-
SS cells and macaque HSC-F, HSR-5.4, and Mn-3942
cells showed no difference in deduced amino acid
sequences between human and macaque CypA (data not
shown). Therefore, there mayb eap o s s i b l ed i f f e r e n t i a l
posttranslational modification of CypA such as acetyla-
tion [41,42] between human and macaque cells or there
may be an additional host cell factor involved in the con-
tribution of CypA to the determination of HIV-1 and SIV
tropism by possibly affecting expression, localization, or
function of CypA or viral capsid proteins.
CypA overexpression increased SIV infection in maca-
que T cells, suggesting that CypA may have different
effects on SIV replication in human and macaque T cells.
TRIM5a is known to restrict HIV-1 infection in macaque
T cells, but this restriction has been shown to be relieved
by CsA-mediated or small interfering RNA-mediated inhi-
bition of CypA function, indicating involvement of CypA
in TRIM5a-mediated restriction of HIV-1 infection in
macaque cells [28,31,32]. Thus, CypA promotes HIV-1
infection in human cells but shows an inhibitory effect on
HIV-1 infection in macaque cells. We attempted to exam-
ine the identification of macaque TRIM5a by PCR from
macaque genomic DNA as reported previously [43] to
i n v e s t i g a t et h ep o s s i b l ee f f e c to fm a c a q u eT R I M 5 a on
CsA-mediated reduction of SIV infection in macaque T
cells, but macaque TRIM5a was identified in HSC-F cells
but not in HSR-5.4 cells, suggesting that the effect of CsA
on SIV replication in macaque T cells obtained from the
present study (Figure 6) may be independent of macaque
TRIM5a restriction (Additional File 2). In owl monkeys,
which belong to new world monkeys, previous reports
revealed the existence of a TRIM-CypA fusion protein
(TRIMCyp) restricting HIV-1 infection, which was
relieved by CsA treatment [44,45]. Recently, TRIMCyp has
been found also in OWM, although OWM TRIMCyp did
n o tr e s t r i c tH I V - 1o rS I V m a creplication [43,46,47]. We
also attempted to examine the identification of OWM
TRIMCyp by PCR using primers on either side of the
CypA insertion as previously reported [43] and the possi-
bility of TRIMCyp expression by immunoblotting with
anti-CypA antibody, but TRIMCyp expression was not
detected in any of the macaque T-cell lines used in the
present study (data not shown) although the CypA inser-
tion was identified in the genome sequence of macaque
T cells (Additional File 2).
T a k e nt o g e t h e r ,t h ep r e s e n ts t u d yr e v e a l sas p e c i e s -
specific effect of CsA on SIV replication. Our results
suggest a contribution of CypA to efficient SIV replica-
tion in macaque cells. In contrast, analysis in human
cells indicated that target cell CypA have no positive
effect on SIV infection; rather, CypB was considered
inhibitory for SIV replication. These results suggest pos-
sible involvement of cyclophilins in the determination of
SIV tropism.
Conclusions
The present study revealed that CsA treatment enhances
SIV replication in human T cells but abrogates SIV repli-
cation in macaque T cells, indicating a host cell species-
specific effect of CsA on SIV replication. CypA knock-
down or overexpression indicated a positive effect of
CypA on SIV infection into macaque but not into human
T cells. These results suggest possible contribution of
CypA to the determination of SIV tropism.
Methods
Analysis of SIV and HIV-1 replication in human and
macaque T cells
HeLa cells were propagated in Dulbecco modified Eagles
medium containing 10% fetal bovine serum (FBS). The
human CEM-SS and A3.01 T cell lines were cultured in
RPMI 1640 containing 10% FBS. Macaque peripheral
blood mononuclear cells (PBMCs) and three macaque T-
cell lines, cynomolgus macaque-derived HSC-F, rhesus
macaque-derived HSR-5.4, and pig-tailed macaque-derived
Mn-3942 were cultured in RPMI 1640 containing 10%
FBS, 10 mM HEPES buffer, 50 μM 2-mercaptoethanol, and
10 U IL-2 per ml [48]. Virus stocks of SIVagm, SIVmac,
and HIV-1 used for analysis of viral replication were pre-
pared by transfection of HeLa cells using LipofectAMINE
LTX PLUS (Invitrogen Corp., Carlsbad, CA) with molecu-
lar clone DNAs of SIVagm9063 [49], SIVmac239 [50], and
HIV-1NL4-3 [51], respectively. An env-defective variant of
SIVagm9063 carrying an insertion of stop codon in the env
gene (nucleotide position 10-15 from start of the env gene)
was constructed by site-directed mutagenesis. Titers of the
virus stocks were quantitated by SIV CA (p27) or HIV-1
CA (p24) enzyme-linked immunosorbent assay (ZeptMe-
trix Corporation, Buffalo, NY) and by determining the
reverse transcriptase (RT) activity. CEM-SS cells (5 × 10
5)
w e r ee x p o s e dt o5 0n go fS I V( p 2 7 )o r1n go fH I V - 1
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5) were incubated with 5 ng
of SIV (p27), and rhesus PBMCs (5 × 10
5) were incubated
with 2 ng of SIV (p27). Virus production was monitored
for 14 d post-infection by measuring RT activity in the cul-
ture supernatants as described previously [52]. In CsA
treatment experiments, cells were cultured in the presence
of 2.5 μM CsA (Sigma-Aldrich, Tokyo, Japan). Mean values
in four independent experiments are shown.
Immunoblot analysis
Immunoblot analysis of cell lysates and viral pellets was
performed as described previously [53]. Briefly, virus
supernatants containing equal RT levels were concen-
trated by centrifugation through 20% sucrose. Pelleted
viruses were analyzed by immunoblotting using anti-CypA
or anti-CA antibodies. A polyclonal anti-SIVagm CA anti-
body provided by Vanessa Hirsch [54], plasma from a SIV-
mac239-infected rhesus macaque, and a monoclonal anti-
HIV-1 p24 antibody (Abcam Inc, Cambridge, MA) were
used to detect SIVagm, SIVmac, and HIV-1 CA, respec-
tively. We used polyclonal anti-CypA antibody (BIOMOL
Research Laboratories Inc., Plymouth Meeting, PA) and
monoclonal anti-a-tubulin antibody (Sigma-Aldrich). A
representative result from four independent experiments
is shown in each figure.
Infectivity analysis
LuSIV cells which are derived from CEMx174 cells and
contain a luciferase indicator gene under the control of the
SIVmac239 LTR were maintained in RPMI 1640 medium
containing 10% FBS and hygromycin B (300 μg/ml) [55].
LuSIV cells were cultured for 24 h after viral infection and
lysed in 1 × reporter lysis buffer (Promega Corp., Madison,
WI). To determine the luciferase activity, lysates were
mixed with luciferase substrate (Promega Corp.) and light
emission was measured in a luminometer (GloMax™ 96
Microplate Luminometer; Promega Corp.). Two sets of
viruses were produced, and each was subjected to two sets
of infection experiments. Thus, mean values of viral cDNA
levels from four independent experiments are shown.
Measurement of viral cDNA levels after viral entry
Viruses were prepared from virus-infected CEM-SS or
HSC-F cells. For infection, 5 × 10
5 target cells were incu-
bated with a SIVagm containing 500 ng of p27, SIVmac
containing 500 ng of p27, or HIV-1 containing 10 ng of
p24 for 24 hr, and then total cellular DNA was extracted
using a DNeasy Tissue Kit (QIAGEN Inc., Valencia, CA).
For CsA treatment of target cells, target cells were prein-
cubated for 24 hr with 2.5 μM CsA (final concentration), a
virus sample was added, and the infected cells (in 2.5 μM
CsA, final concentration) were incubated for 24 hr.
SIVagm, SIVmac, and HIV-1 inactivated by incubation at
65°C for 30 min were used as negative controls. For
quantification of full-length viral cDNA levels by real-time
PCR, primers 5’-GCTTCGGCCTCCATGATA-3’ (nucleo-
tides [nt] 1069-1086) and 5’-TGTTGCTACCGCTT
CCTCTG-3’ (nt 1231-1250) and probes 5’-TAGAAC-
CAACAGGCTCGGAGGGCTTAAA-3’ (nt 1141-1168)
and 5’-AGTCTGTTCAATCTTGTGTGCGTGCTA-
TATTGC-3’ (nt 1170-1202) were used for amplification
and detection of gag region of the SIVagm9063 genome
(GenBank accession number L40990); primers 5’-GAT
CTCTCGACGCAGGACT-3’ (nt 680-698) and 5’-
CCCTGGCCTTAACCGAAT-3’ (nt 844-861) and probes
5’-AGGCTAGAAGGAGAGAGATGGGTGCGAG-3’ (nt
773-800) and 5’-GCGTCGGTATTAAGCGGGGGA-
GAATTAG-3’ (nt 802-829) for amplification and detec-
tion of gag region of the HIV-1NL4-3 genome (GenBank
accession number M19921); primers 5’-GTAGTATGGG-
CAGCAAATGA-3’ (nt 1408-1427) and 5’-TGTTCCTGT
TTCCACCACTA-3’ (nt 1631-1650) and probes 5’-GCAT
TCACGCAGAAGAGAAAGTGAAACA-3’ (nt 1568-
1595) and 5’-ACTGAGGAAGCAAAACAGATAGTGCA-
GAGA-3’ (nt 1597-1626) for amplification and detection
of gag region of the SIVmac239 genome (GenBank acces-
sion number M33262). For quantification of full-length
viral cDNA levels by real-time PCR in CypA-KD human T
cells, primers 5’-AGTGGGAGTTTGTCAATACC-3’ (nt
3787-3806) and 5’-CTGATTTGTTGTGTCCGTTAG-3’
(nt 3954-3974) and probes 5’-AGATGGGGCAGCCAA-
TAGGGAAACTAAATT-3’ (nt 3875-3904) and 5’-
GGAAAAGCAGGATATGTAACTGACAGAGGAAGA-
CAA-3’ (nt 3906-3941) were used for amplification and
detection of pol region of the HIV-1NL4-3 genome. As the
control for standardization, TaqMan Endogenous Control
kit for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used (Applied Biosystems, Inc., Foster City,
CA). Real-time PCR was carried out in a LightCycler 2.0
instrument (Roche Diagnostics Corp., Indianapolis, IN).
The ratios of viral cDNA levels to GAPDH DNA levels are
shown.
Establishment of CypA and CypB knocked-down human T
cell lines
Both human CEM-SS and A3.01 T cells were transduced
with HIV-1-based vectors that confer puromycin resis-
tance and express short hairpin RNAs (shRNA) targeting
human CypA and CypB (Sigma-Aldrich). CypA and CypB
knocked-down cell lines were obtained after selection with
1 μg/ml puromycin. Representative results obtained from
experiments using three CypA and CypB knocked-down
human CEM-SS cell lines are shown.
Exogenous expression of CypA in human and macaque T
cells
CypA cDNAs amplified by PCR were inserted into the
pMACS K
k.HA(C) vector (Miltenyi Biotec GmbH,
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k.HA
(C)-CypA expressing HA-tagged CypA (CypA-HA)
together with a cytoplasmic domain-truncated mouse
major histocompatibility complex class I H-2K
k protein,
respectively. Human CEM-SS or macaque T cells (4 ×
10
6 cells) suspended in 100 μl of nucleofection V solu-
tion with 2 μgo fp M A C SK
k.HA(c)-CypA (CypA-HA)
or pMACS K
k.HA(c) (HA-control) plasmid vector
DNAs were subjected to transfection (nucleofection)
using a Nucleofector device. The nucleofection para-
meter was D-023 for CEM-SS cells and U-029 for HSC-
F cells. After 1 day of culture, transfected cells were
labeled with anti-H-2K
k microbeads (MACSelect K
k
MicroBeads) and enriched by separation using the
MACS Separator (Miltenyi Biotec GmbH). The enrich-
ment rate of transfected cells was determined by detec-
tion of H-2K
k using MACSelect Control FITC Antibody
(Miltenyi Biotec GmbH).
Additional material
Additional file 1: Effect of CypA knock-down on SIV infection in
LLC-MK2 cells. (A) Immunoblot analysis of CypA expression. Lysates of
LLC-MK2 (normal) and CypA-KD cells were subjected to the immunoblot
analysis using anti-a-tubulin, anti-CypA and anti-CypB antibodies (Abcam
Inc., Cambridge, MA) (left panel). The image of one representative blot is
shown. (B) Effect of CypA knock-down on SIV infection in LLC-MK2 cells.
Normal and CypA-KD LLC-MK2 cells were transfected with plasmid
SIVmac239LTR-luc that contains a luciferase indicator gene under the
control of the SIVmac239 LTR. After 24 h, transfected cells were used for
VSVG-pseudotyped SIVagm env(-) virus infection. Infection was
determined 24 h later by measuring the Tat-induced luciferase activity in
the transfected cells. Luciferase activity induced by the virus in normal
LLC-MK2 cells was defined as 100%. Mean values and standard
deviations in three independent experiments are shown.
Additional file 2: Identification of a TRIM5a or a TRIMCyp in
macaque T cells. Total DNA from macaque HSC-F and HSR-5.4 T cells
was harvested. PCR primers on either side of the CypA insertion were
used to detect both a TRIM5a and a TRIMCyp in macaque T cells as
described [43]. H2O denotes water control.
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